The Food and Drug Administration (FDA) is warning healthcare professionals regarding the significantly increased risk for serious and life-threatening cardiovascular (CV) complications associated with normalization of hemoglobin levels in patients receiving erythropoiesis-stimulating agents (ESAs).
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content